TY - JOUR
T1 - A troponin study on patients with ischemic stroke, intracerebral hemorrhage and subarachnoid hemorrhage
T2 - Type II myocardial infarction is significantly associated with stroke severity, discharge disposition and mortality
AU - Alkhachroum, Ayham M.
AU - Miller, Benjamin
AU - Chami, Tarek
AU - Tatsuoka, Curtis
AU - Sila, Cathy
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/6
Y1 - 2019/6
N2 - Troponin elevations due to Type II myocardial infarction (T2MI)are associated with hemorrhagic and ischemic strokes but there is little data on stroke severity, troponin elevation and outcome. We studied 1655 patients from a tertiary medical center between 1/2013-4/2015 using multivariate regression analysis for demographics, vascular risk factors, admission stroke severity, laboratory tests, echocardiogram results and discharge disposition. Troponin levels were classified as normal <0.04 ng/ml and high >0.04 ng/ml (critical if >0.5 ng/ml). A T2MI was diagnosed by a trending troponin elevation; patients with type I MI, patients with subdural and epidural hematoma, or hemorrhagic metastatic disease and patients younger than 18 years old were excluded. We had 818 patients with ischemic stroke, 306 with intracerebral hemorrhage (ICH)and 169 with subarachnoid hemorrhage (SAH). Troponin was elevated (>0.04 ng/ml)in 24.1% of ischemic stroke patients, 27.1% in the ICH group, and in 39% of SAH patients. High initial and peak troponin levels were associated with higher National Institutes of Health Stroke Scale (NIHSS)in patients with ischemic stroke (OR 1.04; CI 95%, 1.02–1.07, p =.001)and (OR 1.05; CI 95%, 1.03–1.07, p <.001). In ICH patients, higher initial and peak troponin levels were not associated with worse ICH scores (OR 1.21; CI 95%, 0.66–2.22, p =.53)and (OR 1.36; CI 95%, 0.77–2.41, p =.29). In SAH patients, higher initial and peak troponin levels was associated with higher Hunt and Hess scores (OR 4.2; CI 95%, 1.6–11.4, p =.005)and (OR 3.14; CI 95%, 1.5–6.5, p =.002). In patients with high troponin levels mortality was 14.7% in ischemic stroke patients, 31.3% in our ICH patients, and 43.8% in our SAH. After adjusting for demographics and clinical risk factors, only high troponin ischemic stroke patients were associated with higher mortality (OR 6.16; CI95%, 2.46–15.4, p <.001), and worse discharge disposition (OR 2.3; CI 95%, 1.19–4.45, p =.01). High troponin levels were not associated with change of outcomes in patients with SAH and ICH after adjusting for demographics and clinical risk factors. Elevated troponin due to T2MI is common in patients with ischemic strokes, ICH, and SAH. It is significantly associated with stroke severity, poor discharge disposition, and high mortality. Troponin levels should be considered on admission for acute strokes.
AB - Troponin elevations due to Type II myocardial infarction (T2MI)are associated with hemorrhagic and ischemic strokes but there is little data on stroke severity, troponin elevation and outcome. We studied 1655 patients from a tertiary medical center between 1/2013-4/2015 using multivariate regression analysis for demographics, vascular risk factors, admission stroke severity, laboratory tests, echocardiogram results and discharge disposition. Troponin levels were classified as normal <0.04 ng/ml and high >0.04 ng/ml (critical if >0.5 ng/ml). A T2MI was diagnosed by a trending troponin elevation; patients with type I MI, patients with subdural and epidural hematoma, or hemorrhagic metastatic disease and patients younger than 18 years old were excluded. We had 818 patients with ischemic stroke, 306 with intracerebral hemorrhage (ICH)and 169 with subarachnoid hemorrhage (SAH). Troponin was elevated (>0.04 ng/ml)in 24.1% of ischemic stroke patients, 27.1% in the ICH group, and in 39% of SAH patients. High initial and peak troponin levels were associated with higher National Institutes of Health Stroke Scale (NIHSS)in patients with ischemic stroke (OR 1.04; CI 95%, 1.02–1.07, p =.001)and (OR 1.05; CI 95%, 1.03–1.07, p <.001). In ICH patients, higher initial and peak troponin levels were not associated with worse ICH scores (OR 1.21; CI 95%, 0.66–2.22, p =.53)and (OR 1.36; CI 95%, 0.77–2.41, p =.29). In SAH patients, higher initial and peak troponin levels was associated with higher Hunt and Hess scores (OR 4.2; CI 95%, 1.6–11.4, p =.005)and (OR 3.14; CI 95%, 1.5–6.5, p =.002). In patients with high troponin levels mortality was 14.7% in ischemic stroke patients, 31.3% in our ICH patients, and 43.8% in our SAH. After adjusting for demographics and clinical risk factors, only high troponin ischemic stroke patients were associated with higher mortality (OR 6.16; CI95%, 2.46–15.4, p <.001), and worse discharge disposition (OR 2.3; CI 95%, 1.19–4.45, p =.01). High troponin levels were not associated with change of outcomes in patients with SAH and ICH after adjusting for demographics and clinical risk factors. Elevated troponin due to T2MI is common in patients with ischemic strokes, ICH, and SAH. It is significantly associated with stroke severity, poor discharge disposition, and high mortality. Troponin levels should be considered on admission for acute strokes.
KW - Intracerebral hemorrhage
KW - Ischemic stroke
KW - Myocardial infarction
KW - Subarachnoid hemorrhage
KW - Troponin
UR - http://www.scopus.com/inward/record.url?scp=85064397777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064397777&partnerID=8YFLogxK
U2 - 10.1016/j.jocn.2019.04.005
DO - 10.1016/j.jocn.2019.04.005
M3 - Article
C2 - 31014907
AN - SCOPUS:85064397777
SN - 0967-5868
VL - 64
SP - 83
EP - 88
JO - Journal of Clinical Neuroscience
JF - Journal of Clinical Neuroscience
ER -